Drugs / ART-I02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03445715 | Jan 2018 → Sep 2019 | rheumatoid arthritis | Arthrogen | Unknown | No outcome recorded |
| Phase 1 | NCT02727764 | Apr 2017 → Sep 2022 | osteoarthritis, rheumatoid arthritis | Arthrogen | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ART-I02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03445715 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “a recombinant adeno-associated virus (AAV) serotype 5 vector expressing interferon (IFN)-β” PMID 34626797 ↗ Oct 2021 |
| Route | Other | “single intra-articular (IA) injection of ART-I02” PMID 34626797 ↗ Oct 2021 |